Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Enanta Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Enanta Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 14 Jan 2022 | Lorem |
| LoA Update: Enanta’s Phase II NASH asset shot to transition to next stage drops by 11 points as company decides to forego monotherapy exploration | 12 Oct 2021 | Reynald Castaneda |
| Enanta’s EDP-938 in RSV draws sceptical expert views on Phase IIb trial outcomes despite more realistic design versus Phase IIa | 15 May 2020 | Bernarda Tundzhay |
| Enanta’s Phase IIa EDP-938 likely to have limited clinical significance for real-world RSV infected patients, future trials, experts say | 01 Feb 2019 | Arafa Salam |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer